News | Proton Therapy | February 10, 2017

Worldwide Survey Says Proton Therapy Will Continue to Grow Rapidly

Proton therapy seen as more efficacious for various cancers than seven years ago

state of the proton therapy market entering 2017, proton therapy, radiation therapy, Robust Insight survey

February 10, 2017 — Independent market research consultancy Robust Insight recently conveyed a survey commissioned by IBA on the state of the proton therapy market entering 2017. The report is based on an online survey among 1,200 hospitals in order to assess how they view proton therapy today and in the future.

Two hundred twenty-two replies from professionals in radiation oncology were received from 205 institutions in 29 countries. Thirty-six percent of the respondents were from centers performing proton therapy. The main highlights of the study are:

  • Sixty-eight percent of respondents believe that proton therapy will continue to grow rapidly in the future;
  • Eighty-two percent of respondents were aware that proton therapy has lower risk of treatment-induced disorders versus conventional radiation therapy;
  • Compared to a similar study in 2009, proton therapy is seen as more efficacious in 2016 than in 2009 for cancers like pediatric, base-of-skull treatment, lung and prostate;
  • Just over 50 percent of the respondents cite limited clinical evidence and limited reimbursement for proton therapy as the biggest barriers impacting the growth of the field; 
  • Seventy-seven percent of respondents believe there will be more and more clinical evidence demonstrating the benefits of proton therapy; and
  • Seventy-three percent believe that the availability of proton therapy will have a growing impact on centers’ reputation.

For more information:

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.